FDA OKs wider use of Novartis' Menveo vaccine

08/2/2013 | Pharmaceutical Business Review Online

The FDA approved the use of Novartis' meningococcal conjugate vaccine Menveo to include toddlers and infants 2 months and older. The vaccine provides protection against meningococcal disease related to four strains of Neisseria meningitidis. The expanded approval was based on data from three trials involving more than 8,700 infants.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA